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Summary 12 
Three distinct RNA polymerases (Pols) transcribe different classes of genes in the 13 
eukaryotic nucleus1. Pol III is the essential, evolutionarily conserved enzyme that 14 
generates short, non-coding RNAs, including transfer RNAs (tRNAs) and 5S 15 
ribosomal RNA (rRNA)2. Historical focus on transcription of protein-coding genes has 16 
left the roles of Pol III in organismal physiology relatively unexplored. The prominent 17 
regulator of Pol III activity, Target of Rapamycin kinase Complex 1 (TORC1), is an 18 
important longevity determinant3, raising the question of Pol III’s involvement in 19 
ageing. Here we show that Pol III limits lifespan downstream of TORC1. We find that 20 
a reduction in Pol III extends chronological lifespan in yeast and organismal lifespan 21 
in worms and flies. Inhibiting Pol III activity in the adult worm or fly gut is sufficient to 22 
extend lifespan, and in flies, longevity can be achieved by Pol III inhibition specifically 23 
in the intestinal stem cells (ISCs). The longevity phenotype is associated with 24 
amelioration of age-related gut pathology and functional decline, dampened protein 25 
synthesis and increased tolerance of proteostatic stress. Importantly, Pol III acts 26 
downstream of TORC1 for lifespan and limiting Pol III activity in the adult gut achieves 27 
the full longevity benefit of systemic TORC1 inhibition. Hence, Pol III is a pivotal output 28 
of this key nutrient signalling network for longevity; Pol III’s growth-promoting, anabolic 29 
activity mediates the acceleration of ageing by TORC1. The evolutionary conservation 30 
of Pol III affirms its potential as a therapeutic target.   31 
	 3 
Main text 32 
The labour of transcription in the eukaryotic nucleus is divided amongst Pol I, II and 33 
III1,4. This specialisation is evident in the biogenesis of the translation machinery, a 34 
task for which all three Pols are co-ordinately required: Pol I generates the 45S pre-35 
rRNA that is subsequently processed into mature rRNAs, Pol II transcribes various 36 
RNAs including messenger RNAs (mRNAs) encoding ribosomal proteins (RPs), while 37 
Pol III provides the tRNAs and 5S rRNA. To match the extrinsic conditions and the 38 
intrinsic need for protein synthesis, this costly process of generating protein synthetic 39 
capacity is tightly regulated by the key driver of cellular anabolism: TORC15,6. The 40 
central position of TORC1 in the control of fundamental cellular processes is mirrored 41 
by the striking impact of its activity on organismal physiology: following the initial 42 
discovery in worms7, the inhibition of TORC1 has been demonstrated to extend 43 
lifespan in all organisms tested, from yeast to mice8,9, with beneficial effects on a range 44 
of age-related diseases and dysfunctions3,10. TORC1 strongly activates Pol III 45 
transcription5,6 and this relationship suggests the possibility that inhibition of Pol III 46 
promotes longevity. Here, we test this hypothesis.  47 
In S. cerevisiae, each of the 17 Pol III subunits is encoded by an essential gene. 48 
We generated a yeast strain in which its largest subunit (C160, encoded by 49 
RPC160/RPO314) is fused to the auxin-inducible degron (AID). The fusion protein can 50 
be	targeted for degradation by the ectopically expressed E3 ubiquitin ligase (OsTir) in 51 
the presence of indole-3-acetic acid (IAA)11 to achieve conditional inhibition of Pol III 52 
(Extended Data Fig. 1a). We confirmed that IAA treatment triggered the degradation 53 
of the fusion protein (Fig. 1a) and observed IAA improve the survival of the RPC160-54 
AID strain upon prolonged culture (Fig. 1b). In addition, IAA treatment of the control 55 
strain lacking the AID fusion reduced its survival, relative to same strain in absence of 56 
	 4 
IAA and the RPC160-AID strain in presence of IAA (Extended Data Fig. 1b). Hence, 57 
Pol III depletion appears to extend yeast chronological lifespan. Note that IAA had no 58 
substantial effect on the survival of a strain carrying the AID domain fused to the 59 
largest subunit of Pol II (RPB220-AID), which appeared to survive better than the 60 
control strain in the presence of IAA (Extended Data Fig. 1a and b), indicating 61 
inhibition of Pol II may also extend chronological lifespan. Yeast chronological lifespan 62 
is a measure of survival in a nutritionally-limited, quiescent population. Replicative 63 
lifespan, on the other hand, measures the number of daughters produced by a single 64 
mother cell in its lifetime. We found no evidence that inhibition of Pol III causes an 65 
increase in yeast replicative lifespan (Extended Data Fig. 1c).  66 
The observed increase in yeast chronological lifespan may simply be indicative 67 
of increased stress resistance and hence bear limited relevance to organismal ageing. 68 
To examine the role of Pol III in organismal ageing directly, we turned to animal 69 
models. We treated C. elegans from the L4 stage with RNAi against rpc-1, the worm 70 
orthologue of RPC160, achieving a partial knockdown of its mRNA (Fig. 1c). This 71 
consistently extended worm lifespan at both 20°C and 25°C (Fig. 1d; Extended Data 72 
Fig. 2a and b, see c for summary of worm lifespans). To reduce Pol III activity in the 73 
fruit fly, we backcrossed a P-element insertion deleting the transcriptional start site of 74 
the gene encoding the Pol III-specific subunit C53 (CG5147EY22749, henceforth called 75 
dC53EY, Extended Data Fig. 3) into a healthy, outbred D. melanogaster population. 76 
Homozygous dC53EY/EY mutants were not viable but heterozygous females had a 77 
partial reduction in dC53 mRNA and lived longer than controls (Fig. 1e and f; see 78 
Extended Data Fig. 4a for summary of fly lifespans). Taken together, our data strongly 79 
indicate that Pol III limits lifespan in multiple model organisms and, conversely, that 80 
partial inhibition of its activity is an evolutionarily conserved longevity intervention. 81 
	 5 
The longevity of an animal can be governed from a single organ. In the worm, 82 
this role is often played by the gut12,13. To restrict the rpc-1 knock-down to the gut, we 83 
used rde-1 null worms whose RNAi machinery deficiency is restored solely in the gut 84 
by gut-specific rde-1 rescue14. rpc-1 RNAi extended the lifespan of this strain, both at 85 
20°C and 25°C (Fig. 2a, Extended Data Fig. 2d). Similarly, in the adult fly, driving an 86 
RNAi construct targeting the RPC160 orthologue (CG17209, henceforth called dC160, 87 
Extended Data Fig. 3) with the mid-gut-specific, RU486-inducible driver (TIGS) 88 
extended female lifespan (Fig. 2b), while the presence of the inducer (RU486) did not 89 
affect survival of the control lines (Extended Data Fig. 4b and c). The longevity 90 
phenotype could also be recapitulated with RNAi against another Pol III subunit (dC53, 91 
Extended Data Fig. 4d), indicating it is not due to off-target effects, or subunit-specific. 92 
The longevity phenotype appeared specific to the gut, since no significant lifespan 93 
extension was observed upon induction of dC160RNAi in the adult fly fat-body and only 94 
a modest, albeit significant extension resulted from neuronal induction (Extended 95 
Data Fig. 4e and f); fat-body and neurons being other two sites often associated with 96 
longevity13.  97 
Worm gut is composed of only post-mitotic cells. In flies, like in mammals, the 98 
adult gut epithelium contains the mitotically active ISCs15. ISC homeostasis is 99 
important for longevity16 and the TIGS gut driver appears active in at least some ISCs 100 
(Extended Data Fig. 5), prompting us to further restrict dC160RNAi induction to solely 101 
this cell type. ISC-specific dC160RNAi, achieved with the GS5961 driver, was sufficient 102 
to promote longevity (Fig. 2c, see Extended Data Fig. 4b and g for controls). In 103 
summary, Pol III activity in the gut limits survival in worms and flies, and in the fly, Pol 104 
III can drive ageing specifically from the gut stem cell compartment.  105 
	 6 
We assessed the consequences of Pol III inhibition in the fly gut. Pol III acts to 106 
generate precursor-tRNAs (pre-tRNAs) that are rapidly processed to mature tRNAs. 107 
Due to their short half-lives, pre-tRNA are suitable readouts of in-vivo Pol III activity. 108 
Profiling the levels of pre-tRNAHis, pre-tRNAAla and pre-tRNALeu, relative to the levels 109 
of U3, a small nucleolar RNA transcribed by Pol II17, revealed a moderate but 110 
significant reduction in Pol III activity upon gut-specific induction of dC160RNAi (Fig. 111 
2d). The three Pols can be directly coordinated for the generation of translation 112 
machinery18. Indeed, Pol III inhibition had knock-on effects on Pol I but not Pol II-113 
generated transcripts, revealing a partial cross-talk (Extended Data Fig. 6a and b). 114 
Consistent with reduced Pol III activity, dC160RNAi reduced protein synthesis in the gut 115 
(Fig. 2e, Extended Data Fig. 6c). These effects (reduction in pre-tRNAs or protein 116 
synthesis) were not observed after feeding RU486 to the driver-alone control 117 
(Extended Data Fig. 6d - f). The reduction in protein synthesis was not pathological: 118 
total protein content of the gut was unaltered; fecundity, a sensitive readout of a 119 
female’s nutritional status, was unaffected; and the flies’ weight, triacylglycerol and 120 
protein levels also remained unchanged (Extended Data Fig. 6g - i). Reduced protein 121 
synthesis can liberate protein-folding machinery from protein production and increase 122 
homeostatic capacity19. Indeed, inducing dC160RNAi in the gut increased the resistance 123 
of adult flies to a proteostatic challenge with tunicamycin (Fig. 2f, and Extended Data 124 
Fig. 6j for TIGS-alone control). Hence, Pol III can fine-tune the rate of protein synthesis 125 
in the adult fly gut, without obvious detrimental outcomes, while increasing resistance 126 
to proteotoxic stress. 127 
Having demonstrated the relevance of Pol III for ageing, we examined whether 128 
it acts downstream of TORC1 for lifespan using the fruit fly. Numerous observations 129 
in several organisms support the model where TORC1 localises on Pol III-transcribed 130 
	 7 
loci and promotes the phosphorylation of the components of Pol III transcriptional 131 
machinery to activate transcription, in part by inhibition of the Pol III repressor, Maf15. 132 
Using chromatin immunoprecipitation (ChIP) with two independently generated 133 
antibodies against Drosophila TOR20,21, we observed the kinase enriched on Pol III-134 
target genes in the adult fly, relative to Pol II targets (Fig. 3a; Extended Data Fig. 7a 135 
to d, and e for mock ChIP). Inhibition of TORC1 by feeding flies rapamycin reduced 136 
the levels of pre-tRNAs in whole flies (Fig. 3b). Rapamycin also reduced pre-tRNA 137 
levels specifically in the gut relative to U3 (Fig 3c). Since rapamycin results in re-138 
scaling of the gut, evidenced by the reduction in the organ’s total RNA content 139 
(Extended Data Fig. 7f), we also confirmed that the drug reduced pre-tRNA levels 140 
relative to total RNA (Extended Data Fig. 7g). Interestingly, rapamycin did not cause 141 
a decrease in 45S pre-rRNA in the gut (Extended Data Fig. 7h and i), suggesting a 142 
lack of sustained Pol I inhibition. Additionally, gut-specific over-expression of Maf1 143 
reduced the levels of pre-tRNAs and extended lifespan (Fig 3d, Extended Data Fig. 144 
7j), confirming this Pol III repressor acts on Pol III in the adult gut. Our data are 145 
consistent with TORC1 driving systemic and gut-specific Pol III activity in the adult fruit 146 
fly. 147 
 To examine whether Pol III is downstream of TORC1 for lifespan, we combined 148 
adult-onset Pol III inhibition with rapamycin treatment. Rapamycin feeding or gut-149 
specific dC160RNAi resulted in the same magnitude of lifespan extension (Fig. 3e). The 150 
two treatments were not additive (see Extended Data Fig. 8a for summary and 151 
statistical analyses), consistent with their acting in the same longevity pathway. The 152 
same was observed with RNAi against dC53 in the gut (Extended Data Fig. 8b), as 153 
well as when dC160RNAi expression was restricted to the ISCs (Fig. 3f). Importantly, 154 
rapamycin feeding also inhibited the phosphorylation of TORC1 substrate, S6 kinase3 155 
	 8 
(S6K), in both the gut and the whole fly, and decreased fecundity, whilst gut-specific 156 
induction of C160RNAi did not (Fig. 3g and h, Extended Data Fig. 8c - f). This confirms 157 
that Pol III inhibition does not impact TORC1 activity, neither locally nor systemically, 158 
and hence, Pol III acts down-stream of TORC1 in ageing (Fig. 3i). 159 
TORC1 inhibition is known to ameliorate age-related pathology and functional 160 
decline of the gut22. We examined whether inhibition of Pol III was sufficient to block 161 
the dysplasia resulting from ISC mis-differentiation by assessing the characteristic, 162 
age-dependent increase in dividing, phospho-histone H3 positive (pH3+) cells16. 163 
Inducing dC160RNAi in the fly gut or solely in the ISCs ameliorated this pathology 164 
(Extended Data Fig. 9a, Fig. 4a and b). The treatment was also sufficient to 165 
counteract the age-related loss of gut barrier function, decreasing the number of flies 166 
displaying extra-intestinal accumulation of a blue food dye (“smurf” phenotype23, 167 
Extended Data Fig. 9b, Fig. 4c). Interestingly, we also found that rpc-1 RNAi feeding 168 
reduced the severity of age-related loss of gut-barrier function in worms (Extended 169 
Data Fig. 9c). In Drosophila, gut health24 and TORC1 inhibition25 are specifically linked 170 
to female survival. Indeed, induction of dC160RNAi in the gut had a sexually dimorphic 171 
effect on lifespan, as the effect on males, albeit significant, was reduced in magnitude 172 
relative to females (Extended Data Fig. 9d). Overall, our data show that gut/ISC-173 
restricted inhibition of Pol III, which extends lifespan, is sufficient to ameliorate age-174 
related impairments in gut health, which may be causative or correlate with this 175 
longevity. 176 
Our study demonstrates that adult-onset decrease in the growth-promoting, 177 
anabolic function mediated by Pol III in the gut, and specifically in the stem cell 178 
compartment, is sufficient to recapitulate the longevity benefits of rapamycin 179 
treatment. Pol III activity is essential for growth6; its detrimental effects on ageing 180 
	 9 
suggest an antagonistic pleiotropy26 where wild-type levels of Pol III activity are 181 
optimised for growth and reproductive fitness in early life but prove detrimental for later 182 
health. We reveal a fundamental role for Pol III in adult physiology, implicating wild-183 
type Pol III activity in age-related stem cell dysfunction, declining gut health and 184 
organismal survival, downstream of nutrient signalling pathways. The longevity 185 
resulting from partial Pol III inhibition in adulthood likely stems from the reduced 186 
provision of protein synthetic machinery, however, differential regulation of tRNA 187 
genes or Pol III-mediated changes to chromatin organisation may also be involved, as 188 
has been suggested in other contexts2. The strong structural and functional 189 
conservation of Pol III in eukaryotes suggests that studies of its influence on 190 
mammalian ageing are warranted and may lead to important therapies.  191 
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Figure Legends 1 
Figure 1 Inhibition of Pol III extends lifespan.  2 
Treatment of the RPC160-AID-myc pADH-OsTir-myc budding yeast strain with 0, 3 
0.125 and 0.25 mM IAA: a, triggers degradation of C160-AID-myc and b, extends its 4 
chronological lifespan, measured as colony formation after normalisation for optical 5 
density and 10-fold serial dilution ([a] and [b] show a representative of two 6 
experimental trials). Feeding N2 worms with E. coli expressing the rpc-1 RNAi 7 
construct from L4 stage: c, reduces the levels of rpc-1 mRNA (p<10-4, two-tailed t-test) 8 
and d, extends their lifespan relative to vector alone at 20°C in presence of FUDR 9 
(p=0.03, log-rank test, n= 86 control, 94 rpc-1 RNAi animals; representative of three 10 
trials). Female flies heterozygous for the dC53EY allele display: e, a reduction in dC53 11 
transcript (p=10-4, two-tailed t-test, 95% confidence intervals [CI] = 0.89-1.1 wt, 0.64-12 
0.71 dC53EY/+) and f, extended lifespan (p=6x10-13, log-rank test, n= 152 control, 144 13 
dC53EY/+ animals; single trial). Bar charts show mean ± Standard Error of the Mean 14 
(SEM), with n= number of biologically independent samples indicated and overlay 15 
showing individual data points. For more detailed demography and summary of worm 16 
and fly lifespan trials see Extended Data Fig. 2c and 4a. For gel source data, see 17 
Sup. Fig. 1. 18 
 19 
Figure 2 Gut-specific inhibition of Pol III extends lifespan, reduces protein 20 
synthesis and increases tolerance to proteostatic stress.  21 
a, Activating RNAi against rpc-1 specifically in the worm gut, using the VP303 strain, 22 
extends worm lifespan at 20°C in presence of FUDR (p=0.02, log-rank test, n= 90 23 
control, 67 rpc-1 RNAi animals; representative of two trials). b, Feeding RU486 to 24 
TIGS>dC160RNAi female fruit flies to induce dC160RNAi in the gut alone extends their 25 
lifespan (p=6x10-16, log-rank test, n= 150 -RU486, 157 +RU486 animals; 26 
representative of three trials).  c, Feeding RU486 to GS5961>dC160RNAi female fruit 27 
flies to induce dC160RNAi in the ISCs alone extends their lifespan (p=2x10-4, log-rank 28 
test, n= 139 -RU486, 142 +RU486 animals; representative of three trials). Inducing 29 
dC160RNAi in the gut with RU486 feeding of TIGS>dC160RNAi females leads to:  d, 30 
reduction in pre-tRNAs (mean ± SEM, p=0.04, Multivariate Analysis of Variance 31 
[MANOVA], n= 10 biologically independent samples per -/+RU486 condition, CI= 0.91-32 
1.1, 0.76-1.0, 0.90-1.1, 0.75-0.92, 0.88-1.1, 0.68-1.0 left to right); e, reduction in gut 33 
protein synthesis, as quantified by ex-vivo puromycin incorporation and western 34 
	 17 
blotting (representative of three biologically independent repeats; see Extended Data 1 
Fig. 6c); f, improved survival in response to tunicomycin challenge (p=3x10-15, log-2 
rank test, n=185 animals per condition; representative of two trials). For more detailed 3 
demography and summary of lifespan trials see Extended Data Fig. 2c and 4a. For 4 
gel source data, see Sup. Fig. 1. 5 
 6 
Figure 3 Pol III acts downstream of TORC1 for lifespan.  7 
a, Relative enrichment of Pol III-transcribed genes is higher than that of Pol II-8 
transcribed genes after ChIP against TOR (p<10-4, Linear Model [LM] with an a priori 9 
contrast, n= 3 biologically independent samples). Rapamycin feeding causes a 10 
decrease in pre-tRNAs relative to U3 in:  b, whole female flies (p=0.01, MANOVA, CI= 11 
0.76-1.2, 0.58-0.79, 0.75-1.3, 0.49-0.79, 0.70-1.3, 0.48-0.78 left to right); c, their guts 12 
(p=0.01, MANOVA, CI= 0.98-1.1, 0.90-1.0, 0.87-1.1, 0.74-0.99, 0.90-1.1, 0.77-0.97 13 
left to right). d, Induction of Maf1 in the guts of TIGS>HA-Maf1 females by RU486 14 
feeding reduces the levels of pre-tRNAs relative to U3 (p=4x10-3, MANOVA, CI= 0.87-15 
1.1, 0.74-1.0, 0.90-1.1, 0.82-1.0, 0.76-1.2, 0.53-1.0 left to right). e, Induction of 16 
dC160RNAi in the adult guts by RU486 feeding of TIGS>dC160RNAi females and 17 
rapamycin feeding both extend lifespan and are not additive (effect of rapamycin 18 
p=2x10-14, effect of RU486 p<2x10-16, interaction p=7x10-9, Cox Proportional Hazards 19 
[CPH], n= 135 control, 144 +RU486, 141 +rapamycin and 146 +RU486 and rapamycin 20 
animals; single trial). f, Induction of dC160RNAi in the ISCs by RU486 in 21 
GS5961>dC160RNAi females and rapamycin both extend lifespan and are not additive 22 
(effect of rapamycin p=8x10-14, effect of RU486 p=2x10-5, interaction p=3x10-7, CPH, 23 
n=  113 control, 130 +RU486, 145 +rapamycin and 144 +RU486 and rapamycin 24 
animals; single trial). Rapamycin but not dC160RNAi induction in the gut by RU468 25 
feeding of TIGS>dC160RNAi females leads to: g, reduction in S6K phosphorylation in 26 
the gut or the whole fly (representative of four biologically independent repeats; see 27 
Extended Data Fig. 6c-f); h, reduction in egg laying (effect of rapamycin p<10-4, 28 
RU486 p=0.87 and interaction p=0.96, LM). i, Model of the relationship between 29 
TORC1, Pol III and lifespan. Bar charts show mean ± SEM, with n= number of 30 
biologically independent samples indicated and overlay showing individual data 31 
points. For more detailed demography, statistics and summary of lifespan trials see 32 
Extended Data Fig. 8a. For gel source data see Sup. Fig.1 33 
 34 
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Figure 4 Stem cell-restricted Pol III inhibition improves age-related dysplasia 1 
and gut barrier function.  2 
dC160RNAi induction in the ISCs of adult GS5961>dC160RNAi females by RU486 3 
feeding supresses age-related accumulation of pH3 positive cells: a, images of pH3 4 
staining in the posterior mid-gut at 70 d of age (white bar = 100 μm, white “>” marks 5 
pH3+ cells, representative of seven -RU486 and nine +RU486 animals); b, the number 6 
of pH3+ cells per gut (effect of age p<10-4, RU486 p=2x10-3, interaction p=2x10-3, LM, 7 
young: 7-9 d, old: 56-70 d, CI= 2.6-8.6, 1.8-9.4, 14-36, 6.0-14 left to right). c, dC160RNAi 8 
induction in the ISCs of adult GS5961>dC160RNAi females by RU486 feeding reduces 9 
the age-related increase in the number of flies with a leaky gut (effect of age p<10-4, 10 
RU486 p=0.09, interaction p=0.01, Ordinal Logistic Regression, young: 21 d, old: 58 11 
d, CI= 0.19-0.28, 1.5-1.8, 18-19, 14-15 % smurf left to right). Bar charts show mean ± 12 
SEM, with n= number of biologically independent animals indicated and overlay 13 
showing individual data points. 14 
 15 
 16 
Methods 17 
Yeast stocks, chronological lifespans and microfluidics assessment 18 
pMK43-based cassette was integrated into w303 MATa leu2-3,112 trp1-1 can1-19 
100 ura3-1 pADH-OsTir-9Myc::ADE2::ade2-1 his3-11,15 to produce RPC160 or 20 
RPB220 C-terminal AID fusions as described11, confirmed by PCR and absence of 21 
growth in presence of 2.5 mM IAA.  22 
Primers for strain construction: 23 
C160 Fw TGTCTATTTGAAAGTCTCTCAAATGAGGCAGCTTTAAAAGCGAACCGTACGCTGCAGGTCGAC 
C160 Rv  AGAAAAATAATACAAATGCTATAAAAAAGTTTAAAAACGACTACTATCGATGAATTCGAGCTCG 
B220 Fw CCAAAGCAAGACGAACAAAAGCATAATGAAAATGAAAATTCCAGACGTACGCTGCAGGTCGAC 
B220 Rv ATATATAATGTAATAACGTCAAATACGTAAGGATGATATACTATAATCGATGAATTCGAGCTCG 
Primers for verification: 24 
C160 Fw  TTGGGTCAAACGATGTCG 
	 19 
B220 Fw CGCCTTCATACTCTCCAAC 
C160/B220 Rv TGCCCATCATGGTACCTG 
For chronological lifespans, the strains were grown to exponential phase 1 
(OD600~0.4) in Synthetic Complete medium (2% glucose, 0.5% ammonium sulphate, 2 
0.17% yeast nitrogen base, 0.001% adenine, uracil, tryptophan, histidine, arginine, 3 
methionine, 0.0025% phenylalanine, 0.003% tyrosine, lysine, 0.004% isoleucine, 4 
0.005% glutamate, aspartate, 0.0075% valine, 0.01% threonine, 0.02% serine and 5 
leucine [w/v]), the culture split and treated with IAA in acetone or acetone alone (0.1%, 6 
day 0) and kept with aeration and shaking at 30°C. Cell were harvested for protein 7 
extraction after 30 min. Cultures essentially reached stationary phase after 24h. The 8 
viability was measured on the indicated days by plating 5 μl of 10-fold serial dilutions 9 
starting from initial concentration corresponding to OD600=0.5 on YEPD plates and 10 
growth for 2 d at 30°C. 11 
For replicative lifespan, cells from single colonies were inoculated in 10 mL of 12 
minimal medium27  with 1% glucose, 0.02% leucine and 0.001% tryptophan, arginine, 13 
histidine and uracil (w/v) and pH 5 maintained with K-Phthalate-KOH buffer. The 10 14 
mL cultures were cultivated overnight in 100 mL shake flasks at 30°C and 300 rpm. 15 
Still exponential, they were diluted next morning to OD600 of 0.005-0.01 and cultivated 16 
for several hours to OD600 of 0.045-0.09 when they were loaded into the microfluidics 17 
device as described28,29. The growth medium was aerated in advance by shaking for 18 
at least two hours. Trapped in the device, the cells were constantly provided with fresh 19 
medium containing the synthetic auxin hormone 1-naphthaleneacetic acid (NAA) at 20 
the concentrations of 0.0005, 0.001, 0.005 or 0.01 mM; the control did not contain 21 
NAA. These concentrations of the hormone span through the dynamic range of the 22 
auxin-based degron system where the degree of protein depletion can be efficiently 23 
	 20 
modulated in the set-up used30. Temperature of 30°C was maintained throughout the 1 
experiment. 2 
Microscopic imaging in the bright field channel was performed for up to 5 days 3 
with the time interval of 5 minutes, using a Nikon Ti-E inverted microscope equipped 4 
with a 40x Nikon Super Fluor Apochromat objective, and halogen lamp with additional 5 
UV-blocking filter. For each cell, the time points of (1) the budding events, (2) the 6 
eventual cell losses due to wash away, or (3) cell death were recorded by visual 7 
inspection of the movies with the help of ImageJ and a custom written macro. For 8 
assessment of cell division times, the first six cell cycles of each cell were used.  9 
 10 
Worm husbandry, lifespans and gut integrity assay. 11 
Prior to experiments animals were maintained at 20°C and grown for at least 12 
three generations with ample OP50 Escherichia coli food to assure full viability. The 13 
rpc-1 RNAi clone, gene code C42D4.8, was obtained from the Ahringer library. 14 
Lifespan assays were performed on HT115 E. coli expressing either the rpc-1 RNAi 15 
plasmid or pL4440 empty vector control. Experiments were carried out at both 20°C 16 
and 25°C. Worms were scored as dead or alive at intervals and worms that crawled 17 
off the plate or died from explosion or bagging phenotypes were censored. rpc-1 RNAi 18 
treatment from L4 stage increased the incidence of a vulval explosion phenotype 19 
(noted in Extended Data Fig. 2c). However, we found that at 25°C this phenotype 20 
was greatly reduced (Extended Data Fig. 2c). For gut-restricted RNAi, the VP303 21 
strain was used14. The “smurf” assay for gut integrity was carried out essentially as 22 
described31. Worms were aged from the L4 stage at 25°C and on the appropriate day 23 
soaked in blue dye for 3 hours. The dye was removed by allowing the worms to crawl 24 
around on a bacterial lawn for 30 minutes prior to microscopy analysis. Individual 25 
	 21 
worms were scored from 0-4 for their degree of “smurfness” with 0 being no blue 1 
beyond the gut barrier and 4 being completely blue. 2 
 3 
Fly husbandry, lifespan, tunicamycin survival, smurf and fecundity assays 4 
The outbred, wild-type stock was collected in 1970 in Dahomey (now Benin) 5 
and has been kept in population cages to maintain lifespan and fecundity at levels 6 
similar to wild-caught flies. w1118 mutation was backcrossed into the stock and 7 
Wolbachia cleared by tetracycline treatment. TIGS32 (a.k.a. TIGS-2), GS596133, 8 
S110634, elavGS35, UAS-HA-Maf136, UAS-dC160RNAi and UAS-dC53RNAi (v30512 and 9 
v103810 from Vienna Drosophila Resource Centre), and dC53EY22749 (CG5147EY22749 10 
from Bloomington Stock Centre) were all backcrossed at least 6 times into the w1118  11 
Dahomey background. 12 
Stocks were maintained and experiments conducted at 25°C on a 12L:12D 13 
cycle at 60% humidity, on SYA food37 containing 10% brewer’s yeast, 5% sucrose, 14 
and 1.5% agar (all w/v; with propionic acid and Nipagin as preservatives).  RU486 15 
(Sigma) and Rapamycin (LC Laboratories, both dissolved in ethanol) were added to 16 
200μM final concentration as required. Tunicamycin (Cell Signaling, DMSO stock) was 17 
used in food with only sugar and agar at concentration of 10mg/l. For control 18 
treatments, equivalent volumes of the vehicle alone were added.  19 
Flies were reared at standardised larval density and adults collected over 12 h, 20 
allowed to mate for 48 h and sorted into experimental vials at a density of 15 flies per 21 
vial (10 flies per vial for RNA extractions). For lifespan experiments, flies were 22 
transferred to fresh vials and their survival scored three times a week. Flies were 23 
transferred onto food containing tunicamycin on day 9 and survival scored once or 24 
twice daily. For smurf assays, at the indicated age the flies were placed on SYA food 25 
	 22 
containing 2.5% (w/v) blue dye (FD&C blue dye no. 1, Fastcolors) for 48 h and scored 1 
as full smurfs if completely blue or partial smurfs if the dye had leaked out of the gut 2 
but not reached the head. Eggs layed over ~24h were counted on day 10. Other 3 
phenotypic tests were performed essentially as described38. 4 
 5 
RNA extraction, qPCR and RNA-Seq 6 
Synchronised populations of worms were placed on control or rpc-1 RNAi at 7 
the L4 stage, grown at 20°C and harvested after 4 days. Ten whole adult flies, or ten 8 
dissected mid-guts, were harvested on day 7-9. Total RNA was isolated using TRIZOL 9 
(Invitrogen). RNA isolation was quantitative – the amount obtained was proportional 10 
to the starting amount. RNA was converted to cDNA using random hexamers and 11 
Superscript II (Invitrogen). Quantitative PCR was performed using Power SYBR Green 12 
PCR Master Mix (ABI), with the relative standard curve method. For worms, rpc-1 13 
transcript levels were normalised to the geometric mean of three stably expressed 14 
reference genes cdc-42, pmp-3 and Y45F10D.4 as described39. For flies, primers 15 
specific for pre-tRNAs were designed based on previous biochemical 16 
characterisation40 or predicted intronic sequences41.  17 
 18 
Primer sequences: 19 
Flies: 20 
Gene of Interest Forward Primer Reverse Primer 21 
dC53 (CG5147) GGGTGACCCAGAGTCCCT GGCGAGCTCAGCGAAGAG 22 
pre-rRNA ITS TTAGTGTGGGGCTTGGCAACCT CGCCGTTGTTGTAAGTACTCGCC 23 
pre-rRNA ETS GTTGCCGACCTCGCATTGTTCG CGGAGCCAAGTCCCGTGTTCAA 24 
pre-tRNAHIS CGTGATCGTCTAGTGGTTAG CCCAACTCCGTGACAATG 25 
pre-tRNAALA CGCACGGTACTTATAATCAG CCAGGTGAGGCTCGAACTC 26 
pre-tRNALEU GCGCCAGACTCAAGATTG TGTCAGAAGTGGGATTCG 27 
	 23 
Tub TGGGCCCGTCTGGACCACAA TCGCCGTCACCGGAGTCCAT 1 
U3  CACACTAGCTGAAAGCCAAG CGAAGCCCTGCGTCCCGAAC 2 
 3 
Worms: 4 
Gene of Interest Forward Primer Reverse Primer 5 
rpc-1 ACGATGGATCACTTGTTTGAAGC GTTCCGACAGTCATTGGGGT 6 
cdc-42 CTGCTGGACAGGAAGATTACG CTCGGACATTCTCGAATGAAG 7 
pmp-3 GTTCCCGTGTTCATCACTCAT ACACCGTCGAGAAGCTGTAGA 8 
Y45F10D.4 GTCGCTTCAAATCAGTTCAGC GTTCTTGTCAAGTGATCCGACA 9 
 10 
For RNA-Seq, RNA was further cleaned up with Qiagen RNeasy (Qiagen), ribo-11 
depleted (Ribo-Zero Gold; Illumina) and sequenced on the Illumina platform at 12 
Glasgow Polyomics (75 bp, pair-end reads). Transcript abundance was estimated with 13 
Salmon42 (https://combine-lab.github.io/salmon/) in quazi-mapping mode onto all 14 
Drosophila cDNA sequences (BDGP6), imported with tximport 15 
(https://bioconductor.org/packages/release/bioc/html/tximport.html) into R 16 
(https://www.r-project.org/) and differential expression determined with DESeq2 17 
(https://bioconductor.org/packages/release/bioc/html/DESeq2.html) using dissection 18 
batch as covariate at 10% false discovery rate43. 19 
 20 
Western blots, immunoprecipitation (IP), S2 dsRNA treatment, translation 21 
assays and ChIP 22 
Proteins were extracted from yeast (10 ml culture), S2 cells (0.1-2 ml culture; 23 
S2 cells were obtained from L. Partridge), 10 flies or ten dissected mid-guts with 24 
trichloroacetic acid, washed and re-suspended in SDS-PAGE loading buffer, 25 
separated by SDS-PAGE and transferred to nitrocellulose. Western blots were 26 
performed with anti-puromycin 12D10 antibody (Millipore), anti-Actin (Abcam, ab1801 27 
	 24 
or ab8224), anti-Myc (Sigma), anti-FLAG (Sigma), anti-phospho-T398-S6K (Cell 1 
Signaling, 9209), anti-S6K antibody44 or anti-TOR antibody20. 2 
IPs were performed on ~2mg of total protein extracted from 2-5 ml of S2 cell 3 
culture (transfected with pAFW-dTOR, treated with dsRNA or untreated) into 50mM 4 
HEPES-KOH pH 8, 100 mM KCl, 5 mM EDTA, 10% glycerol, 0.5% NP-40 and 5 
protease inhibitors with 0.5 μl of anti-dTOR serum20, washed five times with the same 6 
buffer and eluted into SDS-PAGE sample buffer. dsRNA against dTOR corresponds 7 
to fragment 3694-4208 bp of the dTOR open reading frame (this is DRSC02811 from 8 
DRSC/TRiP) and was generated with Megascript RNAi Kit (Thermo Fisher Scientific). 9 
Relative translation rates were determined with the SUnSET assay45: 10 mid-10 
guts of 7 day old flies per sample were dissected in ice-cold PBS and kept in 200 μl of 11 
ice-cold Schneider’s medium followed by incubation in 1 ml of Schneider’s medium 12 
with 10 μg/ml puromycin for 30 min at 25°C. 333 μl of 50 % trichloroacetic acid were 13 
added to stop the reaction. Level of puromycin incorporation was determined by 14 
western blots. 15 
ChIP was performed as described46 on chromatin prepared from 7-day old, 16 
wild-type females using either the anti-TOR antibody raised against a recombinant 17 
TOR protein fragment20, or anti-TOR raised against a peptide21. The mock control 18 
included no antibody. Enrichment after IP was measured relative to input with qPCR. 19 
Primers for 5’ and 3’ end of aop and the P2 InR promoter have been described46,47. 20 
Further primers used: 21 
Gene of Interest Forward Primer Reverse Primer 22 
5S rRNA GCCAACGACCATACCACGCTG AGTACTAACCGCGCCCGACG 23 
tRNAMET CGCAGTTGGCAGCGCGTAAG CCCCGGGTGAGGCTCGAACT 24 
 25 
pH3, Prospero and anti-HRP staining  26 
	 25 
Guts were dissected at indicated ages in ice-cold PBS and immediately fixed 1 
in 4% formaldehyde for 30 minutes. The staining was performed essentially as 2 
described38 with anti-phospho-H3 antibody (Cell Signaling, 9701), anti-Prospero 3 
(Developmental Studies Hybridoma Bank) or anti-HRP48. Guts were mounted in 4 
mounting medium with DAPI (Vectastain). pH3 positive cells per midgut were counted 5 
on a fluorescence microscope. Representative images were acquired with the Zeiss 6 
LSM700 confocal microscope. 7 
 8 
Statistical Analysis 9 
Fly and worm: Survival assays were analysed with log-rank test in Excel 10 
(Microsoft) or JMP (SAS), or with CPH in R using the survival package (https://cran.r-11 
project.org/web/packages/survival/index.html). All other tests were performed in JMP. 12 
Data obtained from dissections, ChIP or westerns were scaled to 13 
dissection/chromatin/replicate batch, except for pH3 counts, to account for batching 14 
effects. MANOVA was used to test for overall effect of RU486 or rapamycin feeding. 15 
For ChIP analysis, “gene” was used as covariate in a LM with an a priory contrast 16 
comparing Pol III- to Pol II-transcribed genes. All regression models had a fully 17 
factorial design.		18 
Yeast microfluidics platform: The data, including the number of buds produced 19 
by each cell and its final event (death or washout), were used for Kaplan-Meier 20 
estimation of survival curves with the Lifelines module (Davidson-Pilon, C., Lifelines, 21 
(2016), Github repository, https://github.com/CamDavidsonPilon/lifelines) in Python. 22 
Plotting and statistical analysis were done in Python. 23 
 24 
Code Availability statement 25 
	 26 
A custom designed code was used to analyse the yeast replicative lifespan 1 
data and will be made available upon reasonable request. 2 
 3 
Data Availability statement 4 
The data that support the findings of this study are available within the paper 5 
and its supplementary information files, including source data for figures, or are 6 
available from the corresponding author upon reasonable request. RNA-Seq data 7 
have been deposited in ArrayExpress: accession code E-MTAB-5252.   8 
	 27 
Extended Data Legends 1 
Extended Data Figure 1. Inhibition of Pol III in yeast.  2 
a, The growth of strains carrying pADH-OsTir with RPC160-AID, RPB220-AID or the 3 
control lacking any AID fusion in the presence or absence of 2.5 mM IAA (single trial). 4 
b, Chronological lifespans of the control and RPB220-AID strains treated with 0, 0.125 5 
and 0.25 mM IAA. Top panels show a representative of two experiments, performed 6 
in parallel with RPC160-AID shown in Fig. 1b. The bottom panels show a single 7 
experiment; the improved survival of RPB220-AID was also observed at a higher IAA 8 
concentration in a second experiment. c, Yeast replicative lifespan (top panels) is not 9 
altered by 1-naphthaleneacetic acid (NAA; analogue of IAA) while cell cycle duration 10 
(bottom panels) is. Both were assessed in the pADH-OsTir RPC160-AID strain on a 11 
microfluidics dissection platform. The concentrations of NAA span the dynamic range 12 
where the degree of protein depletion can be efficiently modulated in this set-up30. The 13 
same control data are shown in each panel for comparison. For each NAA 14 
concentration one experiment was performed. For replicative lifespans, 95% CIs are 15 
indicated by shading, or in brackets for median lifespan, together with log-rank p value. 16 
One-sided Mann-Whitney U test was used to test for significant differences in cell cycle 17 
duration.	 No adjustments were made for multiple comparisons. Dashed lines on 18 
bottom panels represent medians. 19 
 20 
Extended data Figure 2. Inhibition of Pol III extends worm lifespan.  21 
a, Lifespan is extended by feeding N2 worms with rpc-1 RNAi at 20°C in absence of 22 
FUDR (p<10-3 log-rank test, n= 100 control and rpc-1 RNAi treated animals). b, It is 23 
also extended at 25°C in presence of FUDR (p=9x10-3, log-rank test, n= 60 control, 77 24 
rpc-1 RNAi animals). c, Summary of each worm lifespan experiment performed 25 
including the representative trials presented in the figures. Log-rank test p value is 26 
reported. The total number of animals in the trial = dead + censored. In general, fewer 27 
worms were censored in control vs rpc-1 RNAi conditions (average of N2 at 25°C 25% 28 
vs 38%; average of N2 at 20°C 53% vs 73%; average of VP303 at 25°C 3% vs 4% 29 
and average of VP303 at 20°C 37% vs 54%) which is likely to be due to an increased 30 
number of gut explosions in the rpc-1 RNAi treated worms. On average 84.9% of 31 
control and 85.6% of rpc-1 RNAi-treated censored events occurred before the 25th 32 
percentile of the survival curve. Overall, increasing the temperature to 25°C reduced 33 
	 28 
censoring without altering our findings. d, Lifespan is extended when the RNAi against 1 
rpc-1 is restricted to the gut using VP303 strain, at 25°C in presence of FUDR (p=9x10-2 
3, log-rank test, n= 84 control, 103 rpc-1 RNAi treated animals). In (a), (b) and (d), a 3 
representative of two trials is shown. 4 
 5 
Extended data Figure 3. Genes corresponding to unique Pol III subunits in 6 
Drosophila.  7 
The genes encoding the unique Pol III subunits were identified in fruit flies based on 8 
their homology to the yeast genes (BLAST, followed by reverse BLAST), or to the 9 
human orthologue.  10 
 11 
Extended Data Figure 4. Inhibition of Pol III extends fly lifespan.  12 
a, Summary of each fly lifespan experiment performed including the representative 13 
trials presented in the figures but excluding the ones with rapamycin (see Extended 14 
Data Fig. 8a). Experiments were performed on females unless otherwise noted. The 15 
total number of animals in the trial = dead + censored. Log-rank test p value is 16 
reported. RU486 feeding does not have an effect on the lifespans of: b, UAS-17 
dC160RNAi alone (p=0.28, log-rank test, n= 142 -RU486, 146 +RU486 animals); or c, 18 
TIGS alone controls (p=0.41, log-rank test, n= 141 -RU486, 145 +RU486 animals). d, 19 
Inducing dC53RNAi in the gut of TIGS>dC53RNAi females by RU486 extends their 20 
lifespan (p=3x10-6, log-rank test, n= 143 -RU486, 139 +RU486 animals). e, Inducing 21 
dC160RNAi predominantly in the fat body of S1106>dC160RNAi females by RU486 has 22 
no effect on their lifespan (p=0.21, log-rank test, n= 158 -RU486, 155 +RU486 23 
animals). f, Inducing dC160RNAi in neurons of elavGS>dC160RNAi females by RU486 24 
has a modest effect on their lifespan (p=0.03, log-rank test, n= 148 -RU486, 155 25 
+RU486 animals). g, RU486 feeding does not have an effect on the lifespan of the 26 
GS5961 alone control (p=0.88, log-rank test, n= 89 -RU486, 91 +RU486 animals). In 27 
(b) to (g) the single trial performed is shown. 28 
 29 
Extended Data Figure 5. TIGS is active in ISCs.  30 
Images from the posterior region of the midgut showing GFP expression driven by 31 
TIGS in the presence of RU486 and stained with: a, anti-Prospero; b, anti-HRP. GFP 32 
expression can be observed in cells with small nuclei that are Prospero-negative in (a) 33 
and those that stain with anti-HRP in (b). Examples of both types are indicated with a 34 
	 29 
white “>” on the merged images. GFP-positive cells can be observed whose 1 
morphology and staining pattern correspond closely to that of the ISCs (small nucleus, 2 
small cell size, Prospero-negative, anti-HRP-positive [see ref.	48 regarding anti-HRP]). 3 
TIGS has a complex expression pattern, showing variation between neighbouring cells 4 
of the same type and between gut regions. TIGS appears active in at least some ISCs. 5 
Images are representative of two animals. 6 
 7 
Extended Data Figure 6. Effects of dC160RNAi induction in Drosophila adult gut. 8 
Induction of dC160RNAi in the guts of TIGS>dC160RNAi females results in: a, decreased 9 
levels of 45S pre-rRNA (p=4x10-3, MANOVA, CI= 0.95-1.1, 0.85-1.0, 0.95-1.1, 0.81-10 
0.92 left to right; EST = 5’ external transcribed spacer, IST = internal transcribed 11 
spacer), indicating a reduction in Pol I activity as a result of Pol III – Pol I crosstalk; b, 12 
unaltered levels of mRNAs encoding ribosomal proteins (RNA-Seq data, no significant 13 
differences at 10% false discovery rate, DESeq2, n= 3 biologically independent 14 
samples), indicating no crosstalk between Pol III and Pol II; c, decreased protein 15 
synthesis (two further biological repeats and quantification related to Fig. 2e; p=4x10-16 
3, two-sided t-test, n=3 biologically independent samples, CI= 0.65-1.4 -RU486, -17 
0.033-0.68 +RU486). RU486 feeding of TIGS-alone control females does not result in 18 
a significant decrease in: d, levels of pre-tRNAs (p=1x10-4, MANOVA, CI= 0.96-1.0, 19 
1.1-1.2, 0.93-1.1, 1.1-1.2, 0.91-1.1, 1.2-1.3 left to right); e, levels of 45S pre-rRNA 20 
(p=2x10-4, MANOVA, CI= 0.94-1.1, 1.1-1.3, 0.94-1.1, 1.1-1.2 left to right); f, protein 21 
synthesis (p=0.74, two-sided t-test, n=3 biologically independent samples). Induction 22 
of dC160RNAi in the guts of TIGS>dC160RNAi females does not result in significant 23 
changes to: g, total gut protein content (p=0.43, two-sided t-test); h, female fecundity 24 
(p=0.51, two-sided t-test); i, whole-fly body weight, triacylglycerol or protein content 25 
(p=0.58, 0.40, 0.16 respectively, two-sided t-test). j, RU486 feeding of TIGS-alone 26 
control females does not result in increased resistance to tunicamycin (p=0.89, log-27 
rank test, n= 149 -RU486, 153 +RU486 animals; single trial). Bar charts show mean ± 28 
SEM, with n= number of biologically independent samples indicated and overlay 29 
showing individual data points. For gel source data see Sup. Fig. 1. 30 
 31 
Extended Data Figure 7. Regulation of Pol III activity by TORC1 in Drosophila.  32 
a, The antibody raised against a recombinant fragment of Drosophila TOR protein	20 33 
and used for ChIP (Fig. 3a) recognises a single band of the expected size on western 34 
	 30 
blots of S2 cell extracts. b, The same antibody can immunoprecipitate (IP) dTOR from 1 
S2 cells expressing the endogenous and FLAG-tagged dTOR. c, It can also IP 2 
endogenous dTOR and the intensity of this band is reduced upon treatment of S2 cells 3 
with dsRNA against dTOR. For (a) to (c), a single experiment was performed; the 4 
ability of the dTOR RNAi to reduce the intensity of the band was confirmed in an 5 
independent experiment. d, Relative enrichment of Pol III-transcribed genes is higher 6 
than that of Pol II-transcribed genes after ChIP using a second antibody against 7 
Drosophila TOR (raised against a peptide21, p=2x10-4; LM with an a priori contrast, n= 8 
3 biologically independent samples, CI= 1.6-2.6, 0.81-2.3, 1.1-2.7, 0.77-2.8, -0.24-2.5, 9 
-0.065-2.0, 0.13-1.7 left to right). e, No enrichment for Pol III-transcribed genes over 10 
Pol II-transcribed genes is observed after mock ChIP with no antibody (p=0.09, LM 11 
with an a priori contrast, n=3 biologically independent samples). f, Rapamycin feeding 12 
results in a decrease in total RNA content of the adult gut (p<10-4, two-sided t-test). g, 13 
Rapamycin feeding results in reduction of pre-tRNAs relative to total RNA in the fly gut 14 
(p=10-4, MANOVA). Rapamycin feeding does not result in a reduction of pre-rRNA in 15 
the fly gut relative to:h, U3 (p<10-4, MANOVA); i, total RNA (p=0.57, MANOVA). j, 16 
Feeding RU486 to TIGS>HA-Maf1 female fruit flies to induce HA-Maf1 in the gut alone 17 
extends their lifespan (p=0.006, log-rank test, n= 153 -RU486, 146 +RU486 animals; 18 
single trial). Bar charts show mean ± SEM, with n= number of biologically independent 19 
samples indicated and overlay showing individual data points. For gel source data see 20 
Sup. Fig. 1. 21 
 22 
Extended Data Figure 8. Relationship between TORC1 and Pol III.  23 
a, Summary of fly lifespans examining the epistasis between Pol III and TORC1 24 
inhibition (top), including the CPH analyses results (bottom). In the summary (top), 25 
log-rank test p value, relative to -RU486 -rapamycin control, is reported and the total 26 
number of animals in the trial = dead + censored. b, Induction of dC53RNAi in the adult 27 
guts by RU486 feeding of TIGS>dC53RNAi females and rapamycin feeding both extend 28 
lifespan and are not additive (for statistical analysis see [a]; n= 135 control, 135 29 
+RU486, 120 +rapamycin and 137 +RU486 and rapamycin animals; single trial). c - f, 30 
Rapamycin but not induction of dC160RNAi in the guts of TIGS>dC160RNAi females by 31 
RU486 reduces the phosphorylation of S6K in the gut (effect of rapamycin p=3x10-4, 32 
RU486 p=0.77 and interaction p=0.55, LM, CI= 0.51-1.5, 1.0-1.2, 0.33-0.73, 0.08-0.91 33 
left to right) and whole flies (effect of rapamycin p<10-4, RU486 p=0.10 and interaction 34 
	 31 
p=0.16, LM, CI=0.77-1.2, 0.60-1.0, 0.016-0.19, 0.019-0.15 left to right). Further 1 
biological repeats related to Fig. 3g are presented in (c) for the gut and in (d) for the 2 
whole fly. These are quantified in (e) and (f) respectively. In (c) to (f), data from four 3 
biologically independent samples are shown. For gel source data see Sup. Fig. 1. 4 
 5 
Extended Data Figure 9. Inhibition of Pol III in the gut preserves organ health.  6 
a, dC160RNAi induction in the gut of adult TIGS>dC160RNAi females by RU486 feeding 7 
supresses accumulation of pH3 positive cells in old flies (p=1x10-3, 2-tailed t-test, CI= 8 
58-110 -RU486, 10-46 +RU486). b, dC160RNAi induction in the gut of adult 9 
TIGS>dC160RNAi females by RU486 feeding supresses loss of gut barrier function 10 
(number of “smurfs”) in old flies (p=5x10-4, χ2-test, CI=16-26 -RU486, 8.7-16 +RU486 11 
% smurf). c, rpc-1 RNAi suppresses the severity of the age-related loss of gut barrier 12 
function in worms (effect of age p<10-4, rpc-1 RNAi p=0.51, interaction p=0.01, Ordinal 13 
Logistic Regression, CI=5.0-31, 16-50, 24-48, 25-51, 53-78, 34-66 % smurf grades 3 14 
and 4). Age-related loss of gut barrier function has been previously described for 15 
worms31. d, dC160RNAi induction in the gut of adult TIGS>dC160RNAi males by RU486 16 
feeding results in a small but significant extension of lifespan (p=0.03, log-rank-test, 17 
n= 141 –RU486, 139 +RU486 animals; single trial). Bar charts show mean ± SEM with 18 
n= number of animals indicated and overlay showing individual data points.  19 
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